Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index; 8 of the 24 sources its claims cite were checked for support.

Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic

Open access

Abstract

BACKGROUND: Before 2020, mental disorders were leading causes of the global health-related burden, with depressive and anxiety disorders being leading contributors to this burden. The emergence of the COVID-19 pandemic has created an environment where many determinants of poor mental health are exacerbated. The need for up-to-date information on the mental health impacts of COVID-19 in a way that informs health system responses is imperative. In this study, we aimed to quantify the impact of the COVID-19 pandemic on the prevalence and burden of major depressive disorder and anxiety disorders globally in 2020. METHODS: We conducted a systematic review of data reporting the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic and published between Jan 1, 2020, and Jan 29, 2021. We searched PubMed, Google Scholar, preprint servers, grey literature sources, and consulted experts. Eligible studies reported prevalence of depressive or anxiety disorders that were representative of the general population during the COVID-19 pandemic and had a pre-pandemic baseline. We used the assembled data in a meta-regression to estimate change in the prevalence of major depressive disorder and anxiety disorders between pre-pandemic and mid-pandemic (using periods as defined by each study) via COVID-19 impact indicators (human mobility, daily SARS-CoV-2 infection rate, and daily excess mortality rate). We then used this model to estimate the change from pre-pandemic prevalence (estimated using Disease Modelling Meta-Regression version 2.1 [known as DisMod-MR 2.1]) by age, sex, and location. We used final prevalence estimates and disability weights to estimate years lived with disability and disability-adjusted life-years (DALYs) for major depressive disorder and anxiety disorders. FINDINGS: We identified 5683 unique data sources, of which 48 met inclusion criteria (46 studies met criteria for major depressive disorder and 27 for anxiety disorders). Two COVID-19 impact indicators, specifically daily SARS-CoV-2 infection rates and reductions in human mobility, were associated with increased prevalence of major depressive disorder (regression coefficient [B] 0·9 [95% uncertainty interval 0·1 to 1·8; p=0·029] for human mobility, 18·1 [7·9 to 28·3; p=0·0005] for daily SARS-CoV-2 infection) and anxiety disorders (0·9 [0·1 to 1·7; p=0·022] and 13·8 [10·7 to 17·0; p<0·0001]. Females were affected more by the pandemic than males (B 0·1 [0·1 to 0·2; p=0·0001] for major depressive disorder, 0·1 [0·1 to 0·2; p=0·0001] for anxiety disorders) and younger age groups were more affected than older age groups (-0·007 [-0·009 to -0·006; p=0·0001] for major depressive disorder, -0·003 [-0·005 to -0·002; p=0·0001] for anxiety disorders). We estimated that the locations hit hardest by the pandemic in 2020, as measured with decreased human mobility and daily SARS-CoV-2 infection rate, had the greatest increases in prevalence of major depressive disorder and anxiety disorders. We estimated an additional 53·2 million (44·8 to 62·9) cases of major depressive disorder globally (an increase of 27·6% [25·1 to 30·3]) due to the COVID-19 pandemic, such that the total prevalence was 3152·9 cases (2722·5 to 3654·5) per 100 000 population. We also estimated an additional 76·2 million (64·3 to 90·6) cases of anxiety disorders globally (an increase of 25·6% [23·2 to 28·0]), such that the total prevalence was 4802·4 cases (4108·2 to 5588·6) per 100 000 population. Altogether, major depressive disorder caused 49·4 million (33·6 to 68·7) DALYs and anxiety disorders caused 44·5 million (30·2 to 62·5) DALYs globally in 2020. INTERPRETATION: This pandemic has created an increased urgency to strengthen mental health systems in most countries. Mitigation strategies could incorporate ways to promote mental wellbeing and target determinants of poor mental health and interventions to treat those with a mental disorder. Taking no action to address the burden of major depressive disorder and anxiety disorders should not be an option. FUNDING: Queensland Health, National Health and Medical Research Council, and the Bill and Melinda Gates Foundation.

Overview

CoChat Summary

TL;DR

The COVID-19 pandemic was associated with substantial global increases in major depressive disorder and anxiety disorders in 2020, with the largest increases in locations hit hardest by reduced mobility and higher SARS-CoV-2 infection rates. The study estimates an additional 53·2 million major depressive disorder cases and 76·2 million anxiety disorder cases globally in 2020.

Key findings

  • Major depressive disorder prevalence rose by an estimated 27·6% (25·1–30·3), an additional 53·2 million (44·8–62·9) cases, to 3152·9 cases (2722·5–3654·5) per 100 000 population.
  • Anxiety disorders rose by an estimated 25·6% (23·2–28·0), an additional 76·2 million (64·3–90·6) cases, to 4802·4 cases (4108·2–5588·6) per 100 000 population.
  • In 2020, major depressive disorder caused 49·4 million (33·6–68·7) DALYs and anxiety disorders caused 44·5 million (30·2–62·5) DALYs globally.
  • Females and younger age groups were more affected than males and older age groups; daily SARS-CoV-2 infection rates and reductions in human mobility were significantly associated with increased prevalence.

Methods

  • Systematic review of data published Jan 1, 2020–Jan 29, 2021; 5683 unique sources were identified, and 48 studies met inclusion criteria (46 for major depressive disorder, 27 for anxiety disorders).
  • Meta-regression using MR-BRT estimated change in logit prevalence before versus during the pandemic via COVID-19 impact indicators: human mobility, daily SARS-CoV-2 infection rate, and daily excess mortality rate.
  • Pre-pandemic prevalence was estimated with DisMod-MR 2.1 by age, sex, and location; final prevalence estimates and disability weights were used to estimate YLDs and DALYs for 204 countries and territories in 2020.

Limitations

  • The paper states that human mobility and SARS-CoV-2 infection rates are unlikely to capture the full mental health impact of the pandemic across all countries, and that mobile phone tracking may be inaccurate where subgroups have little or no mobile phone use.
  • The paper states that few surveys from low-income and middle-income countries met inclusion criteria, limiting generalisability; it cautions against direct country rankings because of wide uncertainty intervals and data availability.
  • The paper states that most surveys used symptom scales estimating probable cases, requiring the assumption that predictive validity remained constant; it also assumed unchanged severity distribution and could not assess how existing cases changed in severity. The text also makes evident that daily excess mortality was not associated with prevalence change after controlling for the other indicators, likely due to high collinearity.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02143-7

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Global prevalence of major depressive disorder (A) and anxiety disorders (B) before and after adjustment for (ie, during) the COVID-19 pandemic, 2020, by age and sex
Figure 1 Global prevalence of major depressive disorder (A) and anxiety disorders (B) before and after adjustment for (ie, during) the COVID-19 pandemic, 2020, by age and sexCC BY · PubMed Central
Figure 2 Change in the prevalence of major depressive disorder after adjustment for (ie, during) the COVID−19 pandemic, 2020
Figure 2 Change in the prevalence of major depressive disorder after adjustment for (ie, during) the COVID−19 pandemic, 2020CC BY · PubMed Central
Figure 3 Change in the prevalence of anxiety disorders after adjustment for (ie, during) the COVID−19 pandemic, 2020
Figure 3 Change in the prevalence of anxiety disorders after adjustment for (ie, during) the COVID−19 pandemic, 2020CC BY · PubMed Central
Figure 4 Global burden of major depressive disorder and anxiety disorders by age and sex, 2020 Baseline refers to pre-pandemic DALYs and additional refers to additional burden due to the COVID−19 pandemic. DALYs=disability-adjusted life-years.
Figure 4 Global burden of major depressive disorder and anxiety disorders by age and sex, 2020 Baseline refers to pre-pandemic DALYs and additional refers to additional burden due to the COVID−19 pandemic. DALYs=disability-adjusted life-years.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 1 Not valid · 4 Not checked · 13 Own results and interpretations

20 more claims · 3 with their cited sources checked

Create a free account to see all 25 claims and every source verdict.

See all claims — free account

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

2 of 2

Citations

Cites

2 retracted

Show all 42 references

Cited by

See all 5,444

Metadata

Authors
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., Abbafati, C., Adolph, C., Amlag, J. O., Aravkin, A. Y., Bang-Jensen, B. L., Bertolacci, G. J., Bloom, S. S., Castellano, R., Castro, E., Chakrabarti, S., Chattopadhyay, J., Cogen, R. M., Collins, J. K., Dai, X., Dangel, W. J., Dapper, C., Deen, A., Erickson, M., Ewald, S. B., Flaxman, A. D., Frostad, J. J., Fullman, N., Giles, J. R., Giref, A. Z., Guo, G., He, J., Helak, M., Hulland, E. N., Idrisov, B., Lindstrom, A., Linebarger, E., Lotufo, P. A., Lozano, R., Magistro, B., Malta, D. C., Månsson, J. C., Marinho, F., Mokdad, A. H., Monasta, L., Naik, P., Nomura, S., O'Halloran, J. K., Ostroff, S. M., Pasovic, M., Penberthy, L., Reiner Jr, R. C., Reinke, G., Ribeiro, A. L. P., Sholokhov, A., Sorensen, R. J. D., Varavikova, E., Vo, A. T., Walcott, R., Watson, S., Wiysonge, C. S., Zigler, B., Hay, S. I., Vos, T., Murray, C. J. L., Whiteford, H. A., & Ferrari, A. J.
Affiliations
The University of Queensland (AU)
Corresponding author
Santomauro, Damian F
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-11
Volume
398
Issue
10312
Pages
1700-1712
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3203310594
Cited by
5,444
References
42
Citations by year
2026: 663 · 2025: 1095 · 2024: 1383 · 2023: 1359 · 2022: 901 · 2021: 36
FWCI
122.91
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
Funders
Bill & Melinda Gates Foundation
Topics
  • Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords
major depressive disorder, anxiety disorders, COVID-19 pandemic, mental health burden, prevalence, disability-adjusted life years, years lived with disability, SARS-CoV-2 infection rates, human mobility, excess mortality, age and sex differences, global mental health, health system response, mental health professionals, access to mental health care, mental health stigma
MeSH terms
Global Burden of Disease, COVID-19, SARS-CoV-2, Anxiety Disorders, Depression, Humans, Surveys and Questionnaires, Global Health, Prevalence, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-27 (prompt extract-v2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02143-7
The paper
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., Abbafati, C., Adolph, C., Amlag, J. O., Aravkin, A. Y., Bang-Jensen, B. L., Bertolacci, G. J., Bloom, S. S., Castellano, R., Castro, E., Chakrabarti, S., Chattopadhyay, J., Cogen, R. M., Collins, J. K., . . . Ferrari, A. J. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet. https://doi.org/10.1016/s0140-6736(21)02143-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.